$IPCI...week old news but things are happening at IPCI...wont be suprised to here of a partnership or approval before year end...hog
TORONTO, Nov. 18, 2014 (GLOBE NEWSWIRE) -- Intellipharmaceutics International Inc. (IPCI) (TSX:I), a pharmaceutical company specializing in the research, development and manufacture of novel and generic controlled-release and targeted-release oral solid dosage drugs, today announced that it has appointed Domenic Della Penna as its new Chief Financial Officer ("CFO") effective November 24, 2014.
Mr. Della Penna brings considerable expertise and industry experience to the Company. He has been a Chartered Accountant (C.A.) since 1987, a Chartered Professional Accountant (U.S.) since 2012, and holds a Master of Business Administration degree (1988) from the Schulich School of Business at York University (Toronto). He had previously served as CFO of Teva Canada Limited ("Teva") since December 2010, and he had also simultaneously served as Interim CFO of Teva North America Generics in the United States since December 2013. His responsibilities and accomplishments in those roles included enhancements to strategic planning processes and financial systems, integration of assets acquired in the purchase of ratiopharm Canada by Teva, business development, and the negotiation of in-licensing opportunities, mergers and acquisitions. Prior to his time at Teva, Mr. Della Penna was the CFO of Timothy's Coffees of the World, and Vice President of Finance of Diageo Canada Inc.
The CEO of Intellipharmaceutics, Dr. Isa Odidi, said, "We are very pleased to have the opportunity to work with someone having Mr. Della Penna's very substantial financial and strategic planning experience in the area of pharmaceutical development, licensing, manufacturing and supply chain management. We are particularly excited and hope to utilize his experience in strategic planning, and in pharmaceutical manufacturing and supply chain management as we move from being a company largely focused on R&D to one with full research, manufacturing and distribution capabilities."
